DIRS.INFO The most relevant business & tech news

To help you find the lowest prices, our experts are rounding up the best Cyber Monday gaming laptop deals throughout the sale. For more savings on other types of products, visit our guide to the best Cyber Monday deals. View at Amazon What we like Check mark icon A check mark. View at AmazonCyber Monday gaming laptop FAQsIs Cyber Monday a good time to shop for gaming laptop deals? Without getting too technical, here's a rundown of some basic specifications to look for when choosing a gaming laptop.

Persons: it's, Dell Organizations: Business, Buyers, Asus, Intel, AMD, Dell, Nvidia

Our experts are rounding up all the best Black Friday gaming laptop deals so you can snag a great price on a powerful new system. Though more of an entry-level gaming option, the A15 is one of our picks for the best budget gaming laptops you can buy. These Black Friday gaming laptop deals are set to last until midnight PT, but some could extend into the weekend and Cyber Monday. View at Amazon What we like Check mark icon A check mark. View at AmazonBlack Friday gaming laptop FAQsIs Black Friday a good time to shop for gaming laptop deals?

Organizations: Business, Asus, AMD, Intel, Nvidia

Learn moreAs the Amazon Prime Big Deal Days event kicks off, so do Prime Day monitor deals. View at AmazonThe best Amazon Prime Day gaming monitor dealsThe Samsung Neo G9 is 36% off, a fairly common deal for this model, but it's also often found at full price. However, it retains HDR1000 certification, a 1000R certification, AMD FreeSync Premium Pro, and a 240Hz refresh rate. It also has a blazingly fast 360hz refresh rate, making this an ideal high-end gaming monitor. It also supports HDR10 but its contrast performance can't match that of an OLED monitor.

Persons: We've, it's, OLED Organizations: Business, Amazon Prime, Deal, Gamers, Philips, LG, Dell, AMD, Samsung, Asus, Amazon Samsung, Amazon LG, Amazon, Amazon Dell Locations: Amazon

☆ CNBC Daily Open: All key data is in — and it's made the Fed's policy path more uncertain
▼ + stars: | 2024-09-13 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Last Friday, the August employment report showed the number of jobs added was lower than expected but higher than the previous month. Wednesday's CPI report showed the lowest 12-month inflation rate in two-and-a-half years. In short, the data hasn't cleared up whether the Fed will cut by 25 or 50 basis points. They think there's a 57% chance of a 25 point cut and 43% of a 50 point one, according to the CME FedWatch tool.

Persons: Stefani Reynolds, We've, Wednesday's, Jeff Cox, Pia Singh, Sarah Min Organizations: Eccles Federal Reserve, Bloomberg, CNBC, U.S . Federal Reserve, PPI Locations: Washington ,

Prime Day TV dealsThis Prime Day, we're seeing some of the biggest price drops of the year on top TV models from our favorite brands. Prime Day laptop dealsLaptops go on sale year-round, but Prime Day is traditionally the best time of year to make a purchase. Prime Day mattress dealsMattresses go on sale several times a year, but few sales offer as lucrative mattress discounts as Prime Day. Prime Day Amazon device dealsDuring Prime Day, many of the best Amazon devices see their lowest prices ever. Prime Day travel dealsSummer travel is underway, and so are the best Prime Day deals on luggage and backpacks.

Persons: We've, AirPods, we've, Siri, Samsung's, They're, you’ll, He's, Jonathan Adler, it's, dehumidifier, Dyson, vacs, Crisp, we're, Fryer, Foodi, Fry, fryer, they're, Bose Smart, Ray Soundbar, Ray, Anker, You'll, iPhones, MagSafe, Kate Spade, scoped, Amazon Nathan James Hugo Wood Nightstand, Nathan James, waddle, Inaba, haircare, ”, Gabrielle Chase, “, haven't Organizations: Business, Apple, Amazon Apple, Apple Health, Amazon, Amazon LG, Amazon Samsung, Sony WH, Sony, Amazon Sony WH, Amazon Anker, Amazon Bose, Amazon Beats, Samsung, Clarks, Casper, Pillow, Morris, Morris & Co, Dyson, Upright, Toshiba, FlexBrew, Hamilton, LG, Dell, Alexa, Amazon Alexa, Hatch, Amazon Belkin, Apple Watch, Logitech, Seagate, ASUS, Meta, Nintendo, Nova, Nova Pro, Lightspeed, Mac, Google, Galaxy, lounging, packers, Amazon Fisher, Prime, today's, Chatelet Air, Amazon Canada, Amazon Philips, Philips, Amazon Prime, Deal Locations: November's, PopSockets, York

You can grab some of the best deals of the year on gaming laptops from Alienware, Asus, and MSI. View at AmazonThe best Prime Day Apple MacBook dealsIf you're looking to buy any of Apple's MacBook laptops, now would be the time to do it. Apple's M3 MacBook Air offers the best bang for the buck for most people with fantastic performance and quality. Most people don't need the M3 Pro or M3 Max models, unless you want them for graphically intensive work. For gaming, even though Apple has made great strides in gaming performance, there's realistically only one option — a Windows gaming machine.

Persons: it's, Apple Organizations: Business, Asus, Max, Samsung, HP, Dell, Acer, Google, Amazon, MSI, Apple MacBook, Air, MacBook, Apple, MacBook Air, Intel, AMD, AAA, Amazon Prime

View at Amazon What we like Check mark icon A check mark. High-end HDR performanceCheck mark icon A check mark. View at Amazon What we like Check mark icon A check mark. Supports a wide color gamutCheck mark icon A check mark. View at Amazon What we like Check mark icon A check mark.

Persons: Sharp, OLED Organizations: Business, Dell, LG, Asus, Amazon, Amazon LG, AMD, Amazon Dell, Samsung, Amazon Prime

☆ 9 little-known growth stocks with exposure to AI or other transformative trends, according to a top-5% fund manager in the last 10 years
▼ + stars: | 2024-05-22 | by ( James Faris | ) www.businessinsider.com time to read: +6 min

Industry analysts think the AI revolution is still in its early stages, and longtime fund manager Chris Retzler agrees. But the market veteran believes small, under-the-radar growth stocks—not the well-known companies that have already surged — are the best way to play the AI boom. AdvertisementHow to invest in small caps — and where to find themSince 2008, Retzler has single-handedly managed the Needham Small Cap Growth Fund (NESGX). Plus, investors are overlooking small-cap stocks' exposure to key growth opportunities like AI, data center buildouts, military modernization, and telecommunication improvements, in Retzler's view. "Money doesn't go immediately to small caps — it goes to the next market cap, generally," Retzler said.

Persons: —, Chris Retzler, Retzler, he's, Morningstar, doesn't, Rogers, Lumentum, that's, Generac Organizations: Service, Nvidia, Business, Industry, Growth, MKS, Aspen Locations: ROG

AdvertisementIntel 14th-generation Core and Core Ultra CPUs at a glanceIntel Core 14th generation: Intel's most powerful CPUs, but not by muchThe first 14th-generation Intel Core CPUs hit shelves last year. AdvertisementIntel Core 14th generation for desktopsFirst, let's look at Intel's flagship line of consumer-grade desktop CPUs, the Intel Core i5/i7/i9 14th generation. AdvertisementIntel Core Ultra: Better battery life and AI toolsThe Intel Core Ultra is entirely separate from the Intel Core 14th generation. IntelReleasing alongside the Intel Core 14th generation laptop chips are the Intel Core Ultra CPUs, also known by their codename "Meteor Lake." It's intended as a direct successor to the first Intel Core Ultra processors, and will likely be marketed as the "Intel Core Ultra 2."

Persons: it's, they're, There's Organizations: Intel, Dell, MSI, Future Publishing, Puget Systems, K, Razer, Asus, Swift, AMD, Processing Unit, CES, Raptor

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsZURICH, Dec 4 (Reuters) - Roche (ROG.S) agreed to take over obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk (NOVOb.CO) and Eli Lilly. After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added. Among recent deals to acquire obesity drug development projects, AstraZeneca (AZN.L) last month agreed to pay up to $2 billion for the rights to an experimental pill from China's Eccogene. Roche will obtain access to Carmot's current R&D portfolio including all clinical and preclinical assets.

Persons: drugmaker Roche, Arnd, ROG.S, Eli Lilly, Swiss drugmaker, Roche, . New Roche, Thomas Schinecker, Ludwig Burger, Noel Illien, Rachel More, Louise Heavens Organizations: REUTERS, Rights, Carmot Therapeutics, Novo Nordisk, AstraZeneca, Pfizer, Thomson Locations: Basel, Switzerland, Swiss, ., Alzheimer's

☆ Roche’s late obesity punt offers wider market cure
▼ + stars: | 2023-12-04 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Arnd Wiegmann Acquire Licensing RightsLONDON, Dec 4 (Reuters Breakingviews) - Roche’s (ROG.S) foray into the prospective $100 billion obesity market can bring wider benefits. On Monday, the $224 billion Swiss pharma group said it had agreed to take over weight-loss drug developer Carmot Therapeutics for $2.7 billion. Market leader Novo Nordisk (NOVOb.CO) is already selling obesity drugs in the U.S. and parts of Europe. Still, Schinecker’s obesity bet could turn successful if it ends up undercutting obesity pioneers on prices. With over 1 billion people globally classed as seriously overweight, other drugmakers will follow Roche on the obesity bandwagon.

Persons: drugmaker Roche, Arnd, Eli Lilly’s, Thomas Schinecker, Eli Lilly, Eccogene, Roche, Aimee Donnellan, Neiman Marcus, Lisa Jucca, Oliver Taslic Organizations: REUTERS, Reuters, Swiss pharma, Carmot Therapeutics, Novo Nordisk, U.S . Food, Drug Administration, AstraZeneca, Novo, X, Saks, Thomson Locations: Basel, Switzerland, U.S, Europe, Hong Kong

Today's a great day to buy pretty much anything, but the best Cyber Monday laptop deals have the potential to save you hundreds of dollars in a single purchase. Some of the best Cyber Monday laptop deals include an all-time low 27% discount on a Dell Inspiron 16, which offers fantastic specs for everyday users, and $300 off the RTX 4070 model of the Asus ROG Strix G16, a powerful and stylish gaming laptop. We also want to shout out a $130 discount on the Acer Chromebook Plus 515, a deal that turns what was already an affordable model into one of the best budget laptops around. The best Cyber Monday everyday laptop dealsThe best Cyber Monday budget laptop dealsThe best Cyber Monday gaming laptop dealsThe best Cyber Monday 2-in-1 laptop dealsCyber Monday laptop FAQsIs Cyber Monday a good time to buy a laptop? Even high-end gaming laptops fall to midrange or budget levels, which makes Cyber Monday pretty much the best time to buy a new laptop.

Persons: Today's, you've, you'll Organizations: Dell, Asus, Windows, Microsoft, Google

The best Black Friday laptop deals run the gamut from budget to high-end models, and have the potential to save you hundreds of dollars. Some of the best Black Friday laptop deals include a 25% off discount on a Dell Inspiron 16, which offers fantastic specs for everyday users; and $300 off the RTX 4070 model of the Asus ROG Strix G16, a powerful and stylish gaming laptop. Most Black Friday laptop deals will run through tonight, November 24, and a few will last through the weekend and to Cyber Monday. The best Black Friday everyday laptop dealsThe best Black Friday budget laptop dealsThe best Black Friday gaming laptop dealsThe best Black Friday 2-in-1 laptop dealsBlack Friday laptop FAQsIs Black Friday a good time to buy a laptop? What's the difference between a Windows laptop and a Chromebook?

Persons: you'll Organizations: Dell, Asus, Windows, Microsoft, Google

☆ Bayer examines break-up options and prepares to cut management jobs
▼ + stars: | 2023-11-08 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

Bayer will remove multiple layers of management and coordination for a "significant reduction" in the workforce, it said. "We are redesigning Bayer to focus only on what’s essential for our mission – and getting rid of everything else," said Anderson. Analysts have said Bayer shares are trading at a massive discount to rivals in agriculture, pharmaceuticals and consumer health activities, partly weighed down by a preference among many financial investors for pure-play companies. Bayer reported third-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) and adjusted for one-off effects fell 31% to 1.685 billion euros, hit by lower earnings at its Crop Science division. Bayer added that it expects a "soft growth outlook and continued challenges" to profitability next year.

Persons: Wolfgang Rattay, Bill Anderson, Anderson, Bayer, Werner Baumann, Ludwig Burger, Miranda Murray, David Goodman Organizations: Bayer AG, REUTERS, Rights, Bayer, Consumer, Roche, Science, Thomson Locations: Leverkusen, Germany

☆ Siemens Healthineers reviews options for diagnostics unit -source
▼ + stars: | 2023-11-03 | by ( ) www.reuters.com time to read: +1 min

A staffer works on a magnetic resonance imaging machine at a production line of Siemens Healthineers in Shenzhen, China May 25, 2018. REUTERS/Bobby Yip/File Photo Acquire Licensing RightsMUNICH/FRANKFURT, Nov 3 (Reuters) - German medical equipment maker Siemens Healthineers (SHLG.DE) is in the early stages of weighing options for its diagnostics business, which has little overlap with other units, a person familiar with the situation told Reuters. The review could lead to a sale of the unit but all options remain open, the source said. The diagnostics business is also in the middle of restructuring. The listed Siemens subsidiary ranks number two worldwide behind Swiss Roche (ROG.S) in the business of laboratory lines for blood tests.

Persons: Bobby Yip, Alexander Huebner, Victoria Farr, Utkarsh, Bill Berkrot, Jason Neely Organizations: Siemens, REUTERS, Reuters, Bloomberg, Swiss Roche, Thomson Locations: Shenzhen, China, FRANKFURT, Swiss, Munich, Emma, Frankfurt, Bengaluru

☆ Investors reject Sanofi's cure to sickly valuation
▼ + stars: | 2023-10-27 | by ( ) www.reuters.com time to read: +3 min

LONDON, Oct 27 (Reuters Breakingviews) - Sanofi (SASY.PA) investors dislike CEO Paul Hudson’s prescription to reinvigorate the pharmaceutical group’s weak valuation. Analysts polled by LSEG expect the division to hit an EBIT of 1.6 billion euros this year. On listed rival Haleon’s 15.6 times multiple, that business could be worth 25 billion euros. The rest of the Sanofi business may generate EBIT of 11.4 billion euros. The problem is that investors don’t appear to want to take the harsh medicine that leads to a cure.

Persons: Paul Hudson’s, Ernst & Young, Sanofi, EBIT, Roche, Karen Kwok, Francesco Guerrera, Streisand Neto Organizations: Reuters, Sanofi, Ernst, LSEG, Novartis, Novo Nordisk, GSK, AstraZeneca, X, Unilever, Thomson

☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +6 min

Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.

Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris

New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage trial setbacks in the areas of Alzheimer's and cancer immunotherapy last year. The acquired drug, against inflammatory bowel disease such as ulcerative colitis and Crohn's disease, belongs to a class of new treatments known as anti-TL1A antibodies which has attracted major deal activity in the pharma industry. Merck & Co (MRK.N) in April agreed to buy anti-TL1A antibody developer Prometheus Biosciences for $10.8 billion. Inflammatory bowel disease is a group of chronic gastrointestinal disorders with almost 8 million people diagnosed worldwide and 80% of all individuals not experiencing lasting remission, Roche said. "We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," said Roche CEO Schinecker.

Persons: drugmaker Roche, Arnd, New Roche, Thomas Schinecker, Schinecker, Roche, John Revill, Ludwig Burger, Friederike Heine, Jason Neely Organizations: REUTERS, Roivant Holdings, Pfizer Inc, pharma, Sanofi, Merck & Co, Prometheus Biosciences, Thomson Locations: Basel, Switzerland, ZURICH, FRANKFURT, Swiss, U.S, Japan, Zurich, Frankfurt

☆ Roche's $7 bln deal is pricey and partial cure
▼ + stars: | 2023-10-23 | by ( ) www.reuters.com time to read: +2 min

Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsNEW YORK, Oct 23 (Reuters Breakingviews) - Roche (ROG.S) has taken a small step towards curing its drug pipeline problem. JPMorgan analysts estimate that the drug’s U.S. sales could peak at 2.4 billion Swiss francs ($2.7 billion), but will take until 2037 to get there, assuming a 2028 launch. Analysts expect Roche’s pharmaceutical division to generate revenue of almost 45 billion Swiss francs this year, according to estimates compiled by LSEG. With expected free cash flow of around 16 billion Swiss francs this year and next, Roche can afford to buy a little more diversification.

Persons: Roche, Dado Ruvic, Thomas Schinecker, Peter Thal Larsen, Jean, Pierre Mustier, Atos, Jonathan Guilford, Aditya Sriwatsav Organizations: REUTERS, Reuters, Pfizer, U.S, New, JPMorgan, Merck, Prometheus Biosciences, Analysts, LSEG, X, News Corp, Thomson Locations: Swiss, U.S

☆ Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +2 min

Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsOct 19 (Reuters) - Bristol Myers Squibb (BMY.N) said on Thursday the injectable form of its blockbuster cancer drug Opdivo met the main goal in trial that had patients with a type of kidney cancer. "We believe this new option, given as a single injection administered in less than five minutes, could transform the treatment experience for both patients and physicians," Gina Fusaro, an executive at Bristol Myers Squibb, said. The trial also showed a non-inferior response rate to the subcutaneous drug, compared to its intravenous form. Bristol Myers now plans to discuss with regulators the next steps for submission and approval of subcutaneous injections for multiple types of cancers.

Persons: Bristol Myers, Dado Ruvic, Opdivo, Gina Fusaro, Roche, Johnson, Helen Torley, Leroy Leo, Anil D'Silva, Shinjini, Shounak Organizations: Bristol, Bristol Myers Squibb, REUTERS, Therapeutics, U.S, Thomson Locations: Bengaluru

☆ Royalty Pharma to pay $1 bln for Roche's SMA drug royalties
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +1 min

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsOct 19 (Reuters) - Royalty Pharma (RPRX.O) said on Thursday it has purchased additional royalties on Roche (ROG.S) and PTC Therapeutics' (PTCT.O) oral spinal muscular atrophy (SMA) drug for an upfront payment of $1 billion. Spinal muscular atrophy, a leading genetic cause of infant deaths, prevents the body from producing a protein necessary for neuromuscular development. The deal also includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million at a later date, Royalty Pharma said. Royalty Pharma expects to fund the transaction with a combination of existing cash and about $350 million from its revolving credit facility.

Persons: drugmaker Roche, Arnd, Roche, Mariam Sunny, Shilpi Majumdar Organizations: REUTERS, Royalty Pharma, PTC Therapeutics, U.S . Food, Drug Administration, PTC, Thomson Locations: Basel, Switzerland, Bengaluru

☆ Merck KGaA says MS drug has blockbuster potential; key data expected in December
▼ + stars: | 2023-10-19 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Merck, seen as leading the race to win approval for a more targeted type of MS drug, said in April that U.S. regulators had paused enrolment of new patients into a trial testing the drug, evobrutinib, knocking the German drugmaker's share price. "The readout of our Phase 3 study is going to happen in December," she added of the pivotal study in the clinical trials process. Novartis (NOVN.S), also in the race, said in April that no signs of liver damage had been seen in trials testing its anti-inflammatory drug candidate remibrutinib so far. Roche (ROG.S) said in May that its BTK inhibitor against MS, reduced brain lesions associated with the disease in a mid-stage trial and that no new safety concerns had emerged. Reporting by Ludwig Burger Editing by Bill BerkrotOur Standards: The Thomson Reuters Trust Principles.

Persons: Germany's Merck, Belen Garijo, ROG.S, Ludwig Burger, Bill Berkrot Organizations: Germany's, Merck, U.S . Food, Drug Administration, Reuters, Rivals, Sanofi, Novartis, Thomson Locations: FRANKFURT, U.S, Darmstadt

☆ Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales
▼ + stars: | 2023-10-19 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Quarterly sales came in at 14.3 billion Swiss francs ($15.9 billion), the Swiss drugs and diagnostics maker said in a statement, broadly in line with analyst estimates. A high-dose version of Eylea for less frequent injections won U.S. approval in August, creating doubt among analysts that a string of forecast-beating Vabysmo sales can continue. CEO Thomas Schinecker - who is keen to restore Roche's drug development record - said he was looking to acquire drug assets in all stages of development but that there was no rush. He pointed to 10% sales growth during the quarter, excluding currency headwinds and the slump in COVID sales. However, it predicted a less pronounced decline in sales of COVID-19 products of about 4.5 billion Swiss francs, from a previous estimate of a drop of 5 billion francs.

Persons: drugmaker Roche, Arnd, Roche, Regeneron, Thomas Schinecker, Schinecker, Ludwig Burger, Friederike Heine, Elaine Hardcastle Organizations: REUTERS, Bayer, Thomson Locations: Basel, Switzerland, COVID, Swiss

☆ Blood tests needed for widespread Alzheimer's diagnosis on the way
▼ + stars: | 2023-10-11 | by ( Deena Beasley | ) www.reuters.com time to read: +6 min

Several Alzheimer's blood tests are in the works – and one is already being sold to consumers – but none have been established as accurate, formally approved by regulators or reimbursed by insurers. Researchers have been working for years on blood tests for Alzheimer's that can replicate these diagnostic tools. The need for blood tests has become more pressing since the FDA approved Leqembi in July. Accurate blood tests are expected to help identify which dementia patients actually have Alzheimer’s, the most common but not the only cause of dementia. "When there are widely available, scalable, sensitive and specific blood tests it will be an absolute game changer for Alzheimer's patients."

Persons: Denis Balibouse, Eli Lilly, Dr, Sarah Kremen, Eliezer Masliah, Eisai, Michael Irizarry, Roche, Bruce Jordan, Russ Paulsen, Deena Beasley, Caroline Humer, Bill Berkrot Organizations: Memory Centre, of Readaptation, University Hospital, REUTERS, FDA, Sinai Medical Center, Wednesday, Quest Diagnostics, National Institute, Aging, U.S . National Institutes of Health, C2N Diagnostics, Roche Diagnostics, Alzheimer's Association, RAND, Thomson Locations: Geneva, Switzerland, Leqembi, Eisai, Los Angeles, U.S

Amazon's best Prime Day laptop deals include discounts on gaming laptops, touchscreen 2-in-1 laptops, and more. For more savings, check out our live roundup of all the best Prime Day deals. Top 5 Prime Day laptop dealsThe best Prime Day gaming laptop dealsAlienware's x16 is on sale right now for Prime Day. Christopher Gordon/InsiderThe best Prime Day budget laptop dealsThe already budget-friendly Acer Swift Go 14 laptop is even cheaper right now for Prime Big Deal Days. AmazonThe best Prime Day 2-in-1 laptop dealsThe ROG Flow Z13 is a laptop that can function like a tablet.

Persons: We've, Christopher Gordon, they're Organizations: Deal, HP, Asus, Microsoft, Amazon, Prime

Search resuls for: "ROG"

25 mentions found